SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is drawing intense community interest due to the potential for regulatory tailwinds and positive sentiment surrounding the psychedelic-assisted therapy sector. Discussions are currently centered on anticipation for upcoming Phase 3 trial data, speculative interest in potential M&A activity, and active debates among traders regarding the company's long-term commercial strategy versus historical governance concerns.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crow with knife community is actively hyping the token as an essential meme-sector asset, emphasizing its deflationary burn mechanism and multichain presence. Supporters are rallying around the project's grassroots growth and organic cult following, often framing it as a lighthearted yet serious contender in the current meme coin landscape.

Highstreet

Highstreet is actively trending as the community debates its potential for a massive short squeeze following a period of extreme volatility and a sharp price decline. While some traders view the token as a high-conviction recovery play with an oversold chart, others express caution, labeling it a risky asset prone to repeated pump-and-dump cycles.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility as market participants debate whether the recent surge is driven by legitimate event-based utility or market manipulation. While supporters point to global festival partnerships and upcoming events as catalysts for growth, skeptics warn of concentrated token ownership and potential pump-and-dump mechanics amid heavy short-squeeze speculation.

Daddy Darth Sidious

SIDIOUS is gaining traction within the nano-cap meme coin community as traders speculate on a potential rotation from related tokens like MAULCOIN and DARTH. Participants are actively discussing entry points and the prospect of rapid growth, often framed around the concept of the 'Daddy Darth' thematic wars.

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Bright Minds Biosciences Inc

Bright Minds Biosciences is trending as investors frequently compare its potential to previous parabolic biotech runs, citing positive clinical data and strong analyst interest. The community remains focused on the possibility of a buyout or major partnership, often drawing parallels to past small-cap biotechs that saw dramatic, rapid appreciation.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is seeing mixed community sentiment as investors weigh persistent concerns about token dilution against potential catalysts like upcoming exchange-linked ETF filings and ongoing integration with AI-focused infrastructure. While many retail holders express frustration over the asset's lagging performance compared to major tokens, others are actively accumulating, pointing to institutional interest and potential regulatory developments as reasons for long-term optimism.

PolySwarm

PolySwarm is capturing significant community attention as traders analyze the token's cybersecurity utility against a backdrop of ongoing accumulation and low-float volatility. Investors are actively discussing the potential for a breakout, citing technical setups, whale activity, and the increasing demand for decentralized threat detection as primary drivers.

Daddy Darth Vader

Daddy Darth Vader ($DARTH) is trending as part of a highly debated "Daddy Wars" social media rivalry with other community-driven meme coins, fueled by aggressive token giveaways and community-led recruitment. Traders are actively discussing the project's low market cap, its potential as a weekend runner, and conflicting community opinions over whether the project acts as a legitimate trading vehicle or a high-risk pump and dump.

Portillo's, Inc. serves street food through high-energy, multichannel restaurants designed to ignite the senses and create a memorable dining experience. The company was founded on June 8, 2021 and is headquartered in Oak Brook, IL.

Portillos Inc - Ordinary Shares - Class A

Portillo's is trending as investors debate the potential for a rebound, highlighting strong grassroots demand at new locations in Georgia and Illinois versus concerns over leadership transition and margin compression. The community is actively discussing a potential short squeeze, recent insider activity, and the company's long-term expansion strategy as the stock trades near historical lows.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The report, citing sources, said that the federal government is going to look closely at ibogaine’s safety and effectiveness.&nbsp;</li><li>According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.</li><li>The Trump administration does not intend to reclassify the drug for medical use, instead keeping it a Schedule I drug in the leagues of heroin, the report added.</li></ul>Shares of Psyence Biomedical (PBM) more than doubled on Thursday following media reports that the White House is drafting an executive order that would signal the Trump administration's willingness to further U.S. research into the psychedelic compound called ibogaine.Shares of the company, which is advancing nature-derived psilocybin and ibogaine therapies, traded 141% higher at the time of writing, on track for its best session to date if gains hold.In November, the company said that it has established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs, based in Africa, as it prepares for the clinical development of ibogaine for substance use disorders.<h2 class="st-heading-2">Trump’s Upcoming Executive Order</h2>CBS News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/">reported</a>, citing sources, that the federal government is going to look closely at ibogaine’s safety and effectiveness. However, the Trump administration does not intend to reclassify the drug for medical use, instead keeping it a &nbsp;Schedule I drug in the leagues of heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote that have no acceptable medical use and high potential for abuse.According to the report, President Trump is expected to sign the executive order as soon as this week.Ibogaine is a psychoactive indole alkaloid derived from the West African Tabernanthe iboga shrub. Research into its therapeutic applications for post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and depression is ongoing,According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans, though it is unclear how the government will help facilitate further research.An official told CBS News that medical research into ibogaine is in an early phase, but the administration wants to help determine whether it's "snake oil" or a legitimate treatment.Other companies in the field of psychedelics, including Clearmind Medicine (CMND), AtaiBeckley (ATAI), GH Research (GHRS), and Compass Pathways (CMPS) are also trading higher on the news.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PBM stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.A Stocktwits user noted that PBM stock is subject to “wild swings.”<stembedurl>https://www.stocktwits.com/dippin_stocks/message/650500248</stembedurl>Another user opined that the stock is going to be “highly volatile” but reach double digit.<stembedurl>https://www.stocktwits.com/momoneyinfla/message/650499935</stembedurl><a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has fallen by about 95% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/achv-stock-on-track-for-best-day-in-over-7-years-whats-driving-the-rally/cZJvoz0RIDM">ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.

Equity

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.


Compass Pathways (NASDAQ:CMPS) Sees Large Volume Increase - What's Next?

Compass Pathways (NASDAQ:CMPS) Sees Unusually-High Trading Volume - Still a Buy...

Short Interest in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Rises By 39.5%

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest...

Compass Pathways Touts Phase 3 COMP360 Depression Data, Eyes Rolling NDA and 2026 Launch Readiness

Compass Pathways (NASDAQ:CMPS) executives outlined the company's latest Phase 3 depression data and commercialization preparations during a Needham conference session moderated by biotech analyst Ami Fadia.

Phase 3 results highlighted rapid and durable antidepressant effects
CEO Kabir Nath said the...

Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based...

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine analysts that are currently covering the company, Marketbeat Ratings...

Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the...

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees...

Compass Pathways PLC Sponsored ADR $CMPS Shares Bought by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 169.0% during the fourth quarter, according to the company in...

Compass Pathways (NASDAQ:CMPS) Given New $18.00 Price Target at Canaccord Genuity Group

Canaccord Genuity Group cut their price target on shares of Compass Pathways from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday...

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

CMPS
COMPASS Pathways

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CMPS News

CMPSCOMPASS Pathways